23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24 2024 - 3:05PM
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human
genetics and biopharmaceutical company, today announced that two
abstracts on 23ME-00610, a first-in-class anti-CD200R1 antibody,
have been accepted for poster presentations at the 2024 ASCO Annual
Meeting, taking place May 31 - June 4 in Chicago. 23andMe will
present clinical data, including preliminary efficacy and
exploratory biomarker analyses, for the neuroendocrine and ovarian
cancer patient cohorts in the Phase 2a portion of its ongoing Phase
1/2a clinical trial.
23andMe scientists discovered the target for 23ME-00610 through
the Company’s proprietary database of human genetic and health
information. 23andMe has more than 15 million genotyped customers,
roughly 80 percent of whom consent to participate in research. By
analyzing de-identified, aggregate genetic and health data from
consented research participants, 23andMe identified genetic
variants of CD200R1, CD200, and DOK2, the downstream signaling
protein, associated with higher risks of immune disease and lower
risks of cancer, pinpointing CD200R1 as a promising immuno-oncology
target.
Additional preclinical data validated the CD200-CD200R1 pathway
as an immune checkpoint, and potential target for reversing immune
tolerance in cancer as a monotherapy, or in combination with other
therapies. Clinical data from the dose escalation cohort of
patients with advanced solid tumors has shown 23ME-00610 has
favorable pharmacokinetics (PK) for dosing once every three weeks,
expected on-target pharmacologic activity, and a promising safety
and tolerability profile at the preliminary recommended phase 2
dose of 1400 mg.
Details on the posters are below. Posters will be available on
the 23andMe Therapeutics and Investor websites following the
presentations.
Abstract: 4129Title: Safety,
efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1
antibody, in patients with advanced neuroendocrine cancers: Results
from a multi-center multi-country phase 1/2a expansion
cohort.Session Type: Poster Session –
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and
HepatobiliaryDate and Time: June 1, 1:30 - 4:30 PM
CDT
Abstract: 5575Title: Safety,
efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1
antibody, in patients with advanced or metastatic ovarian cancer:
Results from a multi-center multi-country phase 1/2a expansion
cohort.Session Type: Poster Session – Gynecologic
CancerDate and Time: June 3, 9:00 AM - 12:00 PM
CDT
About 23ME-0061023ME-00610 is a first-in-class
anti-CD200R1 monoclonal antibody in the Phase 2a portion of Phase
1/2a clinical development for advanced solid malignancies. CD200R1
was identified as an immuno-oncology (IO) target from the 23andMe
database, with pleiotropic causal variants that have opposing
effect on risks for cancer and immune diseases, referred to as an
IO signature, observed in 3 components in this pathway.
23ME-00610 is designed to bind to CD200R1 and prevent the
interaction of CD200R1 with CD200. The CD200–CD200R1 axis is an
immunological checkpoint that plays a pivotal role in maintenance
of immune tolerance. CD200R1 is an inhibitory receptor expressed on
T cells and myeloid cells while CD200, the ligand for CD200R1, is
highly expressed on certain tumors. In preclinical studies, binding
of tumor-associated CD200 to CD200R1 leads to immune suppression
and decreased immune cell killing of cancer cells. Preclinical data
indicate that this mechanism has the potential to restore the
ability for both T-cells and myeloid cells to kill cancer cells.
Clinical trials registry (clinicaltrials.gov): NCT05199272.
About 23andMe23andMe is a genetics-led consumer
healthcare and biopharmaceutical company empowering a healthier
future. For more information, please visit
www.23andMe.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including, without
limitation, statements regarding its future clinical trials and
plans of 23andMe’s therapeutics business. All statements, other
than statements of historical fact, included or incorporated in
this press release, including statements regarding 23andMe’s
strategy, the plans for and results of its clinical trials and
objectives of management, are forward-looking statements. The words
"believes," "anticipates," "estimates," "plans," "expects,"
"intends," "may," "could," "should," "potential," "likely,"
"projects," “predicts,” "continue," "will," “schedule,” and "would"
or, in each case, their negative or other variations or comparable
terminology, are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements are predictions
based on 23andMe’s current expectations and projections about
future events and various assumptions. 23andMe cannot guarantee
that it will actually achieve the plans, intentions, or
expectations disclosed in its forward-looking statements and you
should not place undue reliance on 23andMe’s forward-looking
statements. These forward-looking statements involve a number of
risks, uncertainties (many of which are beyond the control of
23andMe), or other assumptions that may cause actual results or
performance to differ materially from those expressed or implied by
these forward-looking statements. The forward-looking statements
contained herein are also subject generally to other risks and
uncertainties that are described from time to time in the Company’s
filings with the Securities and Exchange Commission, including
under Item 1A, “Risk Factors” in the Company’s most recent Annual
Report on Form 10-K, as filed with the Securities and Exchange
Commission, and as revised and updated by our Quarterly Reports on
Form 10-Q and Current Reports on Form 8-K. The statements made
herein are made as of the date of this press release and, except as
may be required by law, 23andMe undertakes no obligation to update
them, whether as a result of new information, developments, or
otherwise.
Contacts: Investor Relations Contact:
investors@23andMe.comMedia Contact: press@23andMe.com
23andMe (NASDAQ:ME)
Historical Stock Chart
From May 2024 to Jun 2024
23andMe (NASDAQ:ME)
Historical Stock Chart
From Jun 2023 to Jun 2024